2016
DOI: 10.1016/j.jacl.2016.01.001
|View full text |Cite
|
Sign up to set email alerts
|

Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 34 publications
0
2
0
Order By: Relevance
“…However, our data concur with those by Miller et al [ 43 ] who reported that patients with T1DM and coronary disease have increased Lp-PLA2 after adjustment for HDL cholesterol. In contrast, other studies found no difference in Lp-PLA2 content in HDL from type 1 diabetic patients with and without atherosclerosis [ 44 ]. Lp-PLA2 is mainly bound to small, dense HDL3, and these particles are increased in subjects with atherosclerosis; thus, it is plausible that, even if we did not reach statistical differences in HDL size between the groups with or without stenosis, the increased content of Lp-PLA2 in HDL from subjects with lesions is related to its association to HDL3.…”
Section: Discussionmentioning
confidence: 76%
“…However, our data concur with those by Miller et al [ 43 ] who reported that patients with T1DM and coronary disease have increased Lp-PLA2 after adjustment for HDL cholesterol. In contrast, other studies found no difference in Lp-PLA2 content in HDL from type 1 diabetic patients with and without atherosclerosis [ 44 ]. Lp-PLA2 is mainly bound to small, dense HDL3, and these particles are increased in subjects with atherosclerosis; thus, it is plausible that, even if we did not reach statistical differences in HDL size between the groups with or without stenosis, the increased content of Lp-PLA2 in HDL from subjects with lesions is related to its association to HDL3.…”
Section: Discussionmentioning
confidence: 76%
“…As far as PAF catabolism is concerned, an intracellular PAF-specific acetylhydrolase (PAF-AH) and its plasma isoform lipoprotein-associated phospholipase A 2 (LpPLA 2 ) are the main enzymes for the removal of the acetyl chain at the sn-2 position forming the inactive lyso-PAF [8]. In particular, the enzyme LpPLA 2 is mainly associated with LDL, although it has also been associated with very low-density lipoproteins (VLDLs), intermediate-density lipoproteins, high-density lipoproteins (HDLs), and lipoprotein (a) [9,10]. Many studies have indicated that LpPLA 2 is an independent predictor for coronary artery disease (CAD), with elevated LpPLA 2 activity associated with an increased risk for CAD [11].…”
Section: Introductionmentioning
confidence: 99%